Stefanie Mandl

Company: Indapta Therapeutics

Job title: Chief Scientific Officer

Seminars:

Scientific Rationale for g-NK Cell Therapy in Autoimmune Disease 10:30 am

• G-NK cells are a naturally occurring subset of NK cells that are permanently epigenetically modified through priming in response to CMV • g-NK cells have multiple MOA beyond B-cell depletion: the potential to treat much larger spectrum of autoimmune diseases including multiple sclerosis where T-cells play a larger role • Clinical development plan includes…Read more

day: Day Two Track A, AM